Intra Cellular Therapies reported $-72114000 in Pre-Tax Profit for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Acadia Pharmaceuticals ACAD:US $ -33.57M 79M
Aptinyx Inc APTX:US $ -17667000 2.16M
Biogen BIIB:US $ 874.8M 28.6M
Cytokinetics CYTK:US $ -19.82M 66.93M
Esperion Therapeutics ESPR:US $ -66324000 9.59M
Halozyme Therapeutics HALO:US $ 30.01M 51.62M
Marinus Pharmaceuticals MRNS:US $ -39.43M 20.07M
Minerva Neurosciences NERV:US $ -8.72M 1.05M
Nektar Therapeutics NKTR:US $ -158.97M 68.7M
Neurocrine Biosciences NBIX:US $ -23.3M 44.7M
Novartis NVS:US $ 4129M 217M
Prothena PRTA:US $ -42.57M 4.61M
Redhill Biopharma RDHL:US $ -17.14M 7.24M
Supernus Pharmaceuticals SUPN:US $ 11.32M 3.4M
United Therapeutics UTHR:US $ 150.6M 158.1M
Vanda Pharmaceuticals VNDA:US $ 3.79M 11.35M